SWOG clinical trial number
SWOG-8993
Phase II Study of High Dose Melphalan with Hemopoietic Stem Cell Support and GM-CSF in Refractory Multiple Myeloma (MM)
Closed
Phase
Accrual
100%
Published
Abbreviated Title
Phase II Study of High Dose Melphalan with Hemopoietic Stem Cell Support and GM-CSF in Refractory Multiple Myeloma (MM)
Activated
04/15/1991
Closed
05/01/1996
Research committees
Myeloma
Publication Information Expand/Collapse
1999
High dose melphalan with autotransplantation for refractory multiple myeloma: Results of a Southwest Oncology Group phase II trial.
1997
High dose melphalan with autotransplant for refractory multiple myeloma (MM): Results of a Southwest Oncology Group (SWOG) phase II trial (S8993).
Other Clinical Trials
SWOG Clinical Trial Number
S2213
A Phase III, Randomized Study of Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone (Dara-VCD) Induction Followed by Autologous Stem Cell Transplant or Dara-VCD Consolidation and Daratumumab Maintenance in Patients with Newly Diagnosed AL Amyloidosis
Research Committee(s)
Myeloma
Activated
12/01/2023
Accrual
0%
Open
Phase
SWOG Clinical Trial Number
S2209
A Phase III Randomized Trial for Newly Diagnosed Multiple Myeloma Patients Considered Frail or Ineligible for Stem Cell Transplant Comparing Frontline Regimen Bortezomib-Lenalidomide-Dexamethasone-Lite (VRd-Lite) with Daratumumab-Lenalidomide-Dexamethasone (DRd) Followed by Len+/-Dara (R+/-D) Maintenance
Research Committee(s)
Myeloma
Activated
05/30/2023
Accrual
6%
Open
Phase
SWOG Clinical Trial Number
S2005
A PHASE II RANDOMIZED STUDY COMPARING IBRUTINIB AND RITUXIMAB VS. VENETOCLAX AND RITUXIMAB IN PREVIOUSLY UNTREATED WALDENSTROM'S MACROGLOBULINEMIA (WM) /LYMPHOPLASMACYTIC LYMPHOMA (LPL)
Research Committee(s)
Myeloma
Activated
06/24/2021
Accrual
8%
Open
Phase